UK Regulatory Changes During A Brexit Transition Period – The Government Explains All
Executive Summary
Guidance documents on the regulation of medicines in the UK during a Brexit transition period have been published by the government, covering areas like batch release, drug approvals, and the role of the UK MHRA in the EU regulatory system.
You may also be interested in...
No Brexit Fall Out For UK FIH Trials With Over 40% Jump In Applications
Despite Brexit, the UK is still seen as an attractive place to do clinical research, according to the Medicines and Healthcare products Regulatory Agency. However, the agency's involvement in the EU Voluntary Harmonization Procedure has taken a hit.
‘No-Deal’ Brexit: First Govt Docs This Week May Show Impact On Life Sciences
The BioIndustry Association says life sciences could be among the first sectors to be addressed in the UK government’s planned release of “technical notices” regarding the effects of a “no-deal” Brexit.
The Quality Lowdown: A Week Of International Intrigue
Or perhaps it's been a week of intriguing international events in global drug quality, as an international group works to ratchet up global standards, regulators aim to ease the coming UK/EU divorce and the US and China play their hands in a tariff poker match. Meanwhile, US FDA looks to avert labeler code crisis, Quebec API firm comes clean about missing identity testing, and US firm recalls drug product based on FDA’s API supplier inspection findings.